Check-Cap Ltd. (NASDAQ: CHEK) shares rose as the company announced the publication of CE Mark multicenter clinical study results on C-Scan® in Gut.
The Israel-based Check-Cap is a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule preparation-free, colorectal cancer screening, today announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy, which was submitted for capsule CE Mark, received in January 2018, has been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology.
The article, entitled "A Novel Prep-Less X-Ray Imaging Capsule for Colon Cancer Screening: A Feasibility Study," reported that in 45 analyzed patients, capsule and FIT sensitivity (ability to correctly identify polyps) were 44% and 37%, respectively, with capsule sensitivity increasing to 78% when >50% of the colon surface area was imaged and a linear correlation was observed between imaged area and sensitivity
Said CEO Alex Ovadia, "We are pleased to share the publication of our multicenter clinical study results in Gut, a prestigious, peer-reviewed international medical journal. The data demonstrated the system's safe passage, ultra-low radiation exposure and ability to identify polyps without the need for bowel preparation, a major deterrent to CRC screening.
"We will continue to evaluate our C-Scan Version 3 system in the ongoing EU post approval study, with interim results expected in Q3 of 2018.
The stock rose 45 cents, or 10%, in early morning trade on Tuesday, to $4.93.
